Tri-sprintec and Hypersensitivity - a phase IV clinical study of FDA data

Summary:

Hypersensitivity is reported as a side effect among people who take Tri-sprintec (ethinyl estradiol; norgestimate), especially for people who are female, 30-39 old, have been taking the drug for 1 - 6 months also take Xyrem, and have Narcolepsy.

The phase IV clinical study analyzes which people have Hypersensitivity when taking Tri-sprintec. It is created by eHealthMe based on reports of 1,038 people who have side effects when taking Tri-sprintec from the FDA, and is updated regularly.

What is Tri-sprintec?

Tri-sprintec has active ingredients of ethinyl estradiol; norgestimate. It is often used in birth control. eHealthMe is studying from 1,428 Tri-sprintec users. Check the latest studies of Tri-sprintec.

What is Hypersensitivity?

Hypersensitivity is found to be associated with 2,754 drugs and 2,913 conditions by eHealthMe. Check the latest studies of Hypersensitivity.

On Jul, 11, 2026

1,038 people reported to have side effects when taking Tri-sprintec.
Among them, 15 people (1.45%) have Hypersensitivity.

Could Tri-sprintec cause Hypersensitivity?

Among these 15 people:

How long have people been on Tri-sprintec when they have Hypersensitivity? *

What is the gender of people who have Hypersensitivity when taking Tri-sprintec? *

female: 93.33 %
male: 6.67 %

What is the age of people who have Hypersensitivity when taking Tri-sprintec? *

What are other drugs people take besides Tri-sprintec? *

What are other side effects people have besides Hypersensitivity? *

Headache (pain in head): 4 people, 26.67%
Weight Loss: 3 people, 20.00%
Arrhythmias (irregular heartbeat): 3 people, 20.00%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 3 people, 20.00%
Rheumatic Heart Disease (permanent damage to the heart following rheumatic fever): 3 people, 20.00%
Obstructive Sleep Apnea Syndrome (a sleep disorder that involves cessation or significant decrease in airflow in the presence of breathing effort): 3 people, 20.00%
Bronchial Hyperreactivity: 3 people, 20.00%
Migraine (headache): 3 people, 20.00%
Drug Ineffective: 2 people, 13.33%
Chest Pain: 1 person, 6.67%

What are the existing conditions these people have? *

Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 8 people, 53.33%
Cataplexy (loss of muscle tone accompanied by full conscious awareness): 6 people, 40.00%
Drowsiness: 3 people, 20.00%
Stress And Anxiety: 1 person, 6.67%
Pharyngitis Bacterial (inflammation of the pharynx, causing a sore throat due to bacterial infection): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Tri-sprintec and have Hypersensitivity?

- Check whether Hypersensitivity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tri-sprintec:

Tri-sprintec (1,428 reports)

Hypersensitivity treatments and more:

Hypersensitivity (272,618 reports)

How severe was Hypersensitivity and when was it recovered:

Hypersensitivity in Tri-sprintec

Expand to all the drugs that have ingredients of ethinyl estradiol; norgestimate:

Hypersensitivity and drugs with ingredients of ethinyl estradiol; norgestimate (190 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Tri-sprintec:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hypersensitivity:

Hypersensitivity (2,754 drugs)

Browse all the conditions that are associated with Hypersensitivity:

Hypersensitivity (2,913 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ethinyl estradiol; norgestimate (the active ingredients of Tri-sprintec) and Tri-sprintec (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.